Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials

Schizophrenia Bulletin

Volumn 35, Issue 2, 2009, Pages 443-457

  Correll, Christoph U ^a,b,c   Rummel Kluge, Christine ^d   Corves, Caroline ^e   Kane, John M ^a,b,c   Leucht, Stefan ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Universität München ^*

Author keywords

All cause discontinuation; Antipsychotics; Combination; Efficacy; Monotherapy; Polypharmacy; Schizophrenia; Side effects; Trial methodology

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; RESERPINE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MEDICAL INFORMATION; OUTCOME ASSESSMENT; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DATABASES AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 65349112410     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn018     Document Type: Article

References (64)

1. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10): 1409-1416.
2. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsy-chotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005;353(12):1209-1223.
4. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479.
5. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull. 1988; 24(1):62-67.
6. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610.
7. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715-723.
8. Leucht S, McGrath J, Kissling W. Lithium for Schizophrenia (Cochrane Review). The Cochrane Library. 2003;Issue 3.
9. Leucht S, McGrath J, White P, Kissling W. Carbamazapine for Schizophrenia and Schizoaffective Psychoses (Cochrane Review). The Cochrane Library. Issue 2.
10. Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res. 2004;70(1):33-37.
11. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007;(1): CD006391
12. Cheine M, Ahonen J, Wahlbeck K. Supplementing standard drug treatment of those with schizophrenia with beta-blocking medication (Cochrane Review). The Cochrane Library. 2001; Issue 2.
13. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006;(3):CD005581
14. Riedel M, Strassnig M, Schwarz MJ, Muller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs. 2005;19(10):805-819.
15. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006;Issue 2.
16. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia (Cochrane Review). The Cochrane Library. 2003;Issue 2.
17. Correll CU, Frederickson AM, Kane JM, Manu P. Does an-tipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1-3):91-100.
18. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65(10):1377-1388.
19. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. An-tipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5(1):26.
20. Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res. 2006; 84(1):90-99.
21. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 2003;54(1):55-59.
22. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull. 2002;28:75-84.
23. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65(4):500-508.
24. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
25. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106(5):323-330.
26. Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand. 2002;106(5):321-322.
27. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004;55(9):1006-1013.
28. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325-329.
29. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122-127.
30. Shiloh R. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997;569-573.
31. Josiassen R, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162:130-136.
32. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66(1): 63-72.
33. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New Engl J Med. 2006;354(5):472-482.
34. Adams CE, Coutinho E, Davis JM, et al. The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd; 2006.
35. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 4.2.5. The Cochrane Library. Chi-chester, UK: Wiley and Sons, 2005.
36. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371.
37. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005; 79(2-3):231-238.
38. Der-Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
39. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta analyses. BMJ. 2003;327:557-560.
40. Egger M, Davey mith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
41. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
42. Haase HJ. Zur Dosierung von Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed Fachbuch-Verlagsbuchhandlung; 1983.
43. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667.
44. RevMan Analyses [Computer program]. Version 1.0 for Windows. Review Manager. (RevMan). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2003.
45. Barrett WW, Elsworth RB, Clark LD, Ennis J. Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients. Dis Nerv Syst. 1957;18(6):209-215.
46. Potter WZ, Ko GN, Zhang LD, Yan W. Clozapine in China: a review and preview of US/PRC collaboration. Psychophar-macology. 1989;99:87-91.
47. Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmaco-therapy of chronic schizophrenic patients. Clin Eval. 1976;3: 351-403.
48. Zhang L, Xu Y. A comparison study on treatment effect of clozapine, chlorpromazine and the combination of clozapine and chlorpromazine in schizophrenia. Chin J Nerv Ment Dis. 1989;5(5):306-308.
49. Freudenreich O. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1-3):90-94.
50. Liu Q, Li X, Zhang Y, et al. The treatment effect of combined clozapine and sulpiride on negative symptoms of schizophrenia. Chin J Psychiatry. 1996;29:87-90.
51. Peng H, Kuang Y, Huang X. A control study of risperidone in combination with clozapine in treating refractory schizophrenia. J Mod Clin Med Bioeng. 2001;7(2):100-102.
52. Wang CH, Qin TF, Lin YL, Zhao XF. A clinical effect and following-up study about sulpiride and clozapine for 105 cases of the schizophrenia type. J Xinxiang Med Coll. 1994;11(2):148-151.
53. Xie C, Ni XL. The compared study of treating schizophrenia with risperidone combining clozapine. J Prev Med Inform. 2001;17(4):245.
54. Zhu Y, Zhang S, Zhang D. A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. J Clin Psychol Med. 1999;9(4):204-205.
55. Chien CP, Cole JO. Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study. Am J Psychiatry. 1973;130(1):13-18.
56. Higashima M, Takeda T, Nagasawa T, et al. Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. Eur Psychiatry. 2004;19(6): 380-381.
57. Nishikawa T. Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biol Psychiatry. 1985;11:1161-1166.
58. Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer? Am J Psychiatry. 1964;121:597-600.
59. Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol. 2004;19(1):23-26.
60. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psycho-pharmacology. 2007;27(2):198-204.
61. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006;113(2):142-147.
62. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol. 2007;21(4):453-456.
63. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160(11):2063-2065. Erratum in: Am J Psychiatry 2005;162(9):1774.
64. Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68(3):352-360.